Search for European Projects

Over 40 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Neurovascular Interactions and Pathfinding in the Spinal Motor System (NEVAI)

Start date: Jan 1, 2015, End date: Dec 31, 2019,

"Neurons and blood vessels rely on common guidance signals to wire into elaborate neural and vascular networks that are closely juxtaposed and interdependent: vascular supply of oxygen and nutrients is essential to sustain the high metabolic rate of the nervous system, and conversely neural control of vascular tone is crucial for circulatory homeostasis. However, it remains unclear how the nervous ...
Read Project

 2

 FINISHED 

HSC-based therapies for LSDs: understanding the modalities of cell replacement in the LSD brain for improving therapeutic efficacy (HSCSFORLSDBRAIN)

Start date: Jun 1, 2014, End date: May 31, 2019,

The recent hypothesis that postnatal microglia are maintained independently of circulating monocytes by local precursors that colonize the brain before birth has relevant implications for the treatment of various neurological diseases, including lysosomal storage disorders (LSDs). LSDs are fatal diseases of childhood occurring in 1:5000-7000 live births; in >50% of the cases, LSD patients experien ...
Read Project

 2

 FINISHED 

New experimental therapeutic approaches for Parkinson’s disease by direct DA neuronal reprogramming (REPROPARK)

Start date: Jun 1, 2014, End date: May 31, 2019,

Neurodegenerative diseases cause a significant burden on the elderly population in Europe. Parkinson’s disease (PD) affects 1.2 million people in Europe and with the increasing life expectancy this number will rise, putting more pressure on health care. Treatment of PD is only symptomatic, and therefore, there is an urgent need for more efficient therapies. Degeneration of mesencephalic DA neurons ...
Read Project

 2

 FINISHED 

Treating stroke with Affibody molecules targeting the inflammatory mediator HMGB1 (COUNTERSTROKE)

Start date: Oct 1, 2013, End date: Sep 30, 2018,

The scope of the project is to generate a candidate drug targeting the inflammatory mediator High mobility group box 1 protein (HMGB1) to be used in treatment of stroke. The candidate drug will be validated in animal models, characterized and optimized for subsequent clinical development.Stroke remains a leading cause of death and disability throughout the world. Within EU, more than 500 000 perso ...
Read Project

 6

 FINISHED 

Adoptive engineered T cell Trials to Achieve Cancer Killing (ATTACK)

Start date: Dec 1, 2012, End date: Nov 30, 2017,

The aim of this research is to exploit technology for nucleic acid delivery through the clinical testing of adoptive engineered T cells to treat cancer. Recent innovative developments in cancer gene-immunotherapy have led to very encouraging early clinical results. However, the use of engineered T cells is a challenging and complex field with further development and more proof-of-principle trials ...
Read Project

 16

 FINISHED 

A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation (THE ONE STUDY)

Start date: Nov 1, 2010, End date: Oct 31, 2017,

Preventing immunological rejection of transplanted organs without the need for long-term use of pharmacological immunosuppression is a primary objective in transplantation medicine. Reducing the need for immunosuppression would dramatically improve the outcome for transplant recipients and reduce health costs for society. The means to achieve this goal has not been realised with pharmacological or ...
Read Project

 16

 FINISHED 

In vivo dynamics of antibody responses to lymph-borne viruses (IVM-VIRUS-NAB)

Start date: Feb 1, 2012, End date: Jun 30, 2017,

Objective. Our objective is to elucidate how neutralizing antibody (nAb) responses against live viruses are generated in vivo within lymph nodes (LNs). To this end we will make use of state-of-the-art imaging technology (i.e. multiphoton intravital microscopy [MP-IVM]), fluorescent replication-competent viruses and dedicated mouse models.Background/Rationale. nAbs are critical for virus control, p ...
Read Project

 1

 FINISHED 

Initial Training Network for Neurogical disorders orchestrated by cytoKines (NEUROKINE)

Start date: Jan 1, 2013, End date: May 31, 2017,

Neuroinflammatory disease, in particular multiple sclerosis affects more than 700.000 people within Europe alone. European countries are at the forefront of neuroimmunological research and students in medicine and biology are greatly attracted by the field. Neuroimmunology research further impacts our understanding of the ethiopathology of other CNS-disorders including Alzheimer’s Dementia and Mor ...
Read Project

 13

 FINISHED 

INternational VEnue for poSTgraduate education (INVEST)

Start date: Nov 1, 2011, End date: Apr 30, 2017,

The Università Vita-Salute San Raffaele (USR) is a vibrant and acclaimed private University in Milan, Italy, registered by the Italian Ministry of Research. Together with the San Raffaele Research Institute and the San Raffaele Hospital, both controlled by the San Raffaele Foundation hereafter referred to as HSR, it is part of the San Raffaele Biomedical Science Park, hereafter referred to as SRBS ...
Read Project

 1

 FINISHED 

Development of an integrated SPECT/MRI system for enhanced stratification of brain tumour patients prior to patient-specific radio-chemo therapy and early assessment of treatment efficacy (INSERT)

Start date: Mar 1, 2013, End date: Feb 28, 2017,

"The purpose of the project INSERT is to provide clinically relevant stratification and improved personalized radio-chemo therapy for brain tumour patients using a specifically developed multi-modality imaging tool. The system will also be used for early assessment of treatment efficacy. The initial focus will be on patients with glioma but there is future potential to target a range of tumours in ...
Read Project

 10

 FINISHED 

Imaging of Neuroinflammation in Neurodegenerative Diseases (INMiND)

Start date: Mar 1, 2012, End date: Feb 28, 2017,

The goal of this proposal (INMiND) is to carry out collaborative research on molecular mechanisms that link neuroinflammation with neurodegeneration in order to identify novel biological targets for activated microglia, which may serve for both diagnostic and therapeutic purposes, and to translate this knowledge into the clinic. The general objectives of INMiND are:(i) to identify novel mechanisms ...
Read Project

 32

 FINISHED 

Targeting Brain Inflammation For Improved Functional Recovery in Acute Neurodegenerative Disorders (TARGETBRAIN)

Start date: Dec 1, 2011, End date: Nov 30, 2016,

In acute neurodegenerative disorders, following a sudden insult, neurons are rapidly damaged and usually die but cellular loss can occur hours and days thereafter. These diseases cause massive morbidity and mortality and tremendous economic and societal burden, especially ischemic stroke, which is a leading cause of death and disability with no effective treatment to promote recovery. The brain re ...
Read Project

 10

 FINISHED 

Towards clinical translation of new gene targeting technologies for correcting inherited mutations and empowering adoptive immunotherapy of cancer (SUPERSIST)

Start date: May 1, 2013, End date: Oct 31, 2016,

Substantial evidence supports the therapeutic potential of ex vivo gene therapy based on Hematopoietic Stem Cell (HSC) or T lymphocytes to treat inherited diseases or cancer. Yet, the intrinsic limitations of current gene replacement approaches based on semi-randomly integrating vectors, and the occurrence in some clinical trials of severe adverse events related to gene transfer, prevent safe depl ...
Read Project

 5

 FINISHED 

PROBING THE ROLE OF SODIUM CHANNELS IN PAINFUL NEUROPATHIES (PROPANE STUDY)

Start date: Oct 1, 2013, End date: Sep 30, 2016,

Neuropathic pain is a frequent feature of peripheral neuropathy adversely impacting patients’ quality of life and increasing health care costs. Not all individuals with neuropathy develop pain and it is not possible to predict who is more or less susceptible among those with similar risk exposure. Inability to identify high-risk individuals and drug-responder patients and lack of drugs acting on t ...
Read Project

 9

 FINISHED 

European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR)

Start date: Mar 1, 2012, End date: Jun 30, 2016,

Diabetic retinopathy (DR), the leading cause of blindness among working-age individuals in developed countries has been classically considered to be a microcirculatory disease of the retina. However, there is growing evidence to suggest that retinal neurodegeneration is an early event in the pathogenesis of DR. For this reason, it is reasonable to hypothesize that therapeutic strategies based on n ...
Read Project

 18

 FINISHED 

Advanced Cell-based Therapies for the treatment of Primary ImmunoDeficiency (CELL-PID)

Start date: Nov 1, 2010, End date: Apr 30, 2016,

Primary immune deficiencies (PID) are inherited disorders of the adaptive and innate immune system marked by severe infections, autoimmunity and high risk of cancer. Treatment entails hematopoietic stem cell (HSC) transplantation from allogeneic donors, however in the absence of an HLA compatible donor, HSCT outcome is limited by delayed or suboptimal reconstitution and complications. SCID-X1 and ...
Read Project

 20

 FINISHED 

Imaging liver immunopathology by intravital microscopy (IVM): a new approach to study the pathogenesis of hepatitis B virus (HBV) infection (Liver IVM and HBV)

Start date: Sep 1, 2010, End date: Mar 31, 2016,

Overall objective and Specific Aims. The overall objective of this proposal is to elucidate the pathogenesis ofHBV infection with the ultimate hope that this knowledge will lead to the development of new therapeuticstrategies to terminate persistent infection and its attendant costs and complications. Our approach is to dissectpoorly understood cellular and molecular pathways responsible for both ...
Read Project

 2

 FINISHED 

Towards Safe and Effective Hematopoietic Stem Cell Gene Therapy: Targeting Integration to Genomic Safe Harbors and Exploiting Endogenous microRNA to Regulate Transgene Expression (TARGETINGGENETHERAPY)

Start date: May 1, 2010, End date: Jan 31, 2016,

Hematopoietic stem cell gene therapy has a tremendous potential to treat human disease. Yet, in conjunction with the first successful results in the clinic, severe adverse events linked to the gene transfer protocol were reported. Recently, we provided proof-of-principle of two new powerful strategies to improve the efficacy and safety of gene transfer: 1) regulating transgene expression by exploi ...
Read Project

 3

 FINISHED 

EUropean TRanslational training for Autoimmunity & Immune manipulation Network (EUTRAIN)

Start date: Jan 1, 2012, End date: Dec 31, 2015,

Immune-mediated inflammatory diseases (IMID) are important health challenges in Europe and beyond, afflicting an estimated 5-8% of the total population. IMID with an onset during childhood such as Juvenile Idiopathic Arthritis (JIA) cause particular concern as pediatric patients form an especially vulnerable group. Currently there is no safe and cost-effective cure for JIA and related juvenile IMI ...
Read Project

 11

 FINISHED 

Beta Cell Therapy in Diabetes (BETACELLTHERAPY)

Start date: Jan 1, 2010, End date: Jun 30, 2015,

Type 1 diabetes is a serious chronic disease with major health risks and heavy burden on patients and society. It is caused by massive immune-mediated loss of insulin-producing beta cells in the pancreas that can so far not be locally corrected. A cellular allotransplant in the liver can install a new beta cell mass but the size is insufficient and the procedure faces limitations of donor shortage ...
Read Project

 18

 FINISHED 

Combined Highly Active Anti-retroviral Microbicides (CHAARM)

Start date: Jan 1, 2010, End date: Jun 30, 2015,

This proposal is for a large scale collaborative project in which we propose both to develop novel microbicides directed against new intracellular targets and to investigate novel combinations of highly active anti-retroviral drugs which may be particularly effective as microbicides. Combinations may enhance efficacy but equally importantly will increase the genetic barrier to the development of r ...
Read Project

 34

 FINISHED 

Hydroxitirosol, a new generation of microbicides targeting HIV through antiviral and anti-inflammatory pathways (AIM-HIV)

Start date: Dec 1, 2012, End date: May 31, 2015,

Since the first cases of AIDS were reported 30 years ago, HIV remains a difficult target for the research field. Although there is no cure for AIDS, HIV infection can be prevented, however in many countries across the world access to prevention and treatment services is limited. Global leaders have pledged to work towards universal access to HIV prevention and care, so that millions of deaths can ...
Read Project

 4

 FINISHED 

Visualizing liver immunopathology progression during hepatitis B infection by liver Intravital Microscopy (IVM) (Liver IVM)

Start date: May 6, 2013, End date: May 5, 2015,

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infect the liver, and are unique in their capacity to cause persistent infection, cirrhosis, and liver cancer. The lack of experimental approaches to study these infections, due to the limited host range to humans and chimpanzees, have hampered the understanding of fundamental issues regarding their pathogenesis. It is now clear that both infecti ...
Read Project

 1

 FINISHED 

Atopic diseases in changing climate, land use and air quality (ATOPICA)

Start date: Oct 1, 2011, End date: Mar 31, 2015,

There is an urgent need to understand how global and regional climate, land use and air quality changes will impact human health. Our consortium constitutes an innovative and multidisciplinary approach to explore the combined pan-European impact of changes in climate, land use and air pollution on allergen pollen-induced diseases through a chain of quantitative physical and statistical models. We ...
Read Project

 11

 FINISHED 

Effect of PTPN22 on Treg to Teff equilibrium in human and murine autoimmune diabetes (PTPN22 in T1D)

Start date: Apr 1, 2011, End date: Mar 31, 2015,

"Type 1 diabetes (T1D) is a chronic inflammatory disease, where predisposing genetic factors along with environmental influences result in loss of immunological tolerance and destruction of insulin-producing beta cells. Genetic studies have identified three main T1D susceptibility loci, the human leukocyte antigens (HLA), insulin and most recently PTPN22, which encodes for Lyp/Pep, a lymphoid tyro ...
Read Project

 2

 FINISHED 

EUROCANCER STEMCELL TRAINING NETWORK (EuroCSCTraining)

Start date: Jan 1, 2011, End date: Dec 31, 2014,

The recent identification of tumor initiating (TIC) or cancer stem cells (CSC) has opened a new area of research for scientists interested in cancer. Understanding the biology of cancer stem cells has already unraveled pathways and potential targets. However, accumulating data has underscored the complexity of the CSC research area and prompts hence the need for well-structured networks to provid ...
Read Project

 11

 FINISHED 

Intelligent Surgical Robotics (I-SUR)

Start date: Mar 1, 2011, End date: Dec 31, 2014,

Description I-SUR will develop advanced technologies for automation in minimally invasive and open surgery. Currently, automation is not used in the operating room for a number of technical and legal reasons, but it may provide a solution to improve performance and efficiency without increasing operating costs. I-SUR aims at breaking new gro ...
Read Project

 9

 FINISHED 

Activation of vasculature associated stem cells and muscle stem cells for the repair and maintenance of muscle tissue (Endostem)

Start date: Jan 1, 2010, End date: Dec 31, 2014,

We propose to develop new strategies to mobilize skeletal muscle tissue-associated stem cells as a tool for efficient tissue repair. This will be combined with exploring novel approaches that limit tissue damage, and will focus on agents that modify muscle and muscle vasculature progenitor cells. These molecules include nitric oxide associated with non-steroidal anti-inflammatory drugs, HMGB1, Cri ...
Read Project

 22

 FINISHED 

Aberrant gene expression and muscular dystrophy: role of non-coding RNAs and alternative splicing in the pathogenesis and potential therapies (NCRNAS-SPLICING-FSHD)

Start date: Sep 1, 2008, End date: Aug 31, 2014,

Our goal is to characterize the molecular pathogenesis of facioscapulohumeral muscular dystrophy (FSHD) in order to develop possible therapeutic approaches. FSHD is the third most important myopathy. Currently, no therapeutic treatment is available for FSHD. Unlike the majority of genetic diseases, FSHD is not caused by mutation in a protein-coding gene. Instead, FSHD is the result of a complex ep ...
Read Project

 2

 FINISHED 

Adaptive Strategies for Sustainable Long-Term Social Interaction (ALIZ-E)

Start date: Mar 1, 2010, End date: Aug 31, 2014,

Description From theory to practice: Methods for an adaptive and prolonged child-robot interaction The goal of ALIZ-E is to develop novel methods for developing and testing interactive, mobile robots which will be able to socially interact with human users over extended periods of time, i.e. a pos ...
Read Project

 12

 FINISHED 

Targeting the tumour microenvironment to improve pancreatic cancer prognosis (EPC-TM-Net)

Start date: Feb 1, 2011, End date: Jul 31, 2014,

Pancreatic cancer is one of the most lethal human cancers with a five-year survival rate of less than 5%. Late presentation and a high level of resistance to chemotherapeutic drugs are among the major reasons for this dismal prognosis. The presence of the highest degree of desmoplasia among all solid tumours and the fact that chronic inflammatory pancreatic disease is associated with an increased ...
Read Project

 17

 FINISHED 

Immunomodulatory Effects of Exercise in Type 1 Diabetes (IMMEEDIA)

Start date: Jul 1, 2010, End date: Jun 30, 2014,

"Diabetes is a major metabolic disease with huge costs for healthcare system throughout the EU and worldwide. Type 1 Diabetes (T1DM) is a chronic condition in which pancreas produces little or no insulin, believed to result from a disorder of immunoregulation. For decades it has been known that regular aerobic exercise improves insulin sensitivity in diabetic patients, reducing insulin requirement ...
Read Project

 5

 FINISHED 

Pan-European network for the study and clinical management of drug resistant tuberculosis (TB PAN-NET)

Start date: Jan 1, 2009, End date: Jun 30, 2014,

"This proposal will establish an integrated and synergistic network to address the challenge of multiple drug resistant tuberculosis (MDR-TB) facing the EU. The objective will be attained through the establishment of a European consortium of expert partners with extensive experience in the conduct of basic and clinical research relating to MDR-TB, TB control and epidemiology. This Consortium will ...
Read Project

 32

 FINISHED 

Role of secretases in myelination (Secretases & Myelin)

Start date: May 1, 2010, End date: Apr 30, 2014,

The development of glial cells, oligodendrocytes (OL) in CNS and Schwann cells (SC) in PNS, critically depends on axonal contact. Gliogenesis and the phenotype of myelinating glia are regulated by axons. Glial cells promote neuronal survival, regulate the organization of myelinated axons and promote axonal differentiation and myelin sheath production.We recently showed that type III NRG1, a member ...
Read Project

 2

 FINISHED 

Quantifying transcription factor search mechanism by three-dimensional single molecule tracking (SMT of TFs)

Start date: Apr 16, 2012, End date: Apr 15, 2014,

Transcription factors (TFs) are capable to identify their target sites on DNA in a extremely efficient fashion. The observation that a simple 3D diffusion search cannot account for such efficient targeting has led to different mechanisms to be proposed in the last decades, including compact exploration induced by facilitated diffusion (i.e. combination of 1D sliding and 3D diffusion) or by fracta ...
Read Project

 2

 FINISHED 

"""Role of Nonlinear Dynamics of NF-kB in Inflammation""" (NonLin-kB)

Start date: Mar 15, 2012, End date: Mar 14, 2014,

NF-kB is a family of transcription factors that coordinately control hundreds of genes involved in many steps of inflammatory processes, from microbial killing to cancer. When inflammatory stimuli hit the cell surface, NF-kB undergoes several cycles of nucleus-to-cytoplasm translocations, resulting in oscillations of nuclear NF-kB concentrations and activity.At single cell level, live imaging and ...
Read Project

 1

 FINISHED 

Optimization of stem cell therapy for clinical trials of degenerative skin and muscle diseases (OptiStem)

Start date: Jan 1, 2009, End date: Dec 31, 2013,

This proposal aims to develop and implement efficacy of clinical trials with adult, tissue stem cells for degenerative diseases of epithelia and skeletal muscle. Extraordinary progress in the understanding of several key features of stem cells has been rapidly translated into novel cell therapy protocols that have yielded positive results in pre-clinical models of genetic and acquired diseases and ...
Read Project

 20

 FINISHED 

Trustworthy Clouds – Privacy and Resilience for Internet-scale Critical Infrastructure (TCLOUDS)

Start date: Oct 1, 2010, End date: Sep 30, 2013,

Protecting critical infrastructures providing communications, energy, or healthcare presents increasing ICT challenges as ICT itself has become vital to them. Internet-scale ICT infrastructures ("infrastructure clouds") promise scalable virtualised computing, network, and storage resources over the Internet. They provide scalability and cost-efficiency but pose significant new privacy and resilien ...
Read Project

 16

 FINISHED 

Advanced Teaching and TRaining for Adoptive Cell Therapy (ATTRACT)

Start date: Oct 1, 2009, End date: Sep 30, 2013,

Considerable resources are devoted to fighting cancer throughout Europe, yet these efforts are not producing the results that health practitioners and citizens might expect. This is partly due to the fragmentation and duplication of research efforts within Member states and the lack of co-ordination at European level. However it can also be attributed to the need to retain and most importantly dev ...
Read Project

 16

 FINISHED 

Novel therapeutic antibodies for multiple myeloma (MMSC)

Start date: Oct 1, 2009, End date: Sep 30, 2013,

"Multiple Myeloma (MM) is an incurable plasma cell neoplasm with a median survival of 3 years. A critical step towards the development of more effective therapies is the identification of dominantly acting oncogenes. We have implemented an integrated oncogenomic approach that utilizes high-resolution gene-specific array-CGH and comprehensive expression profiling to identify the spectrum of geneti ...
Read Project

 2